60
Participants
Start Date
December 18, 2023
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2026
BET Bromodomain Inhibitor ZEN-3694
Given PO
Biopsy Procedure
Undergo biopsy
Biospecimen Collection
Undergo collection of blood samples
Computed Tomography
Undergo CT
Electrocardiography
Undergo ECG
Magnetic Resonance Imaging
Undergo MRI
Tuvusertib
Given PO
X-Ray Imaging
Undergo x-ray
RECRUITING
NRG Oncology, Philadelphia
SUSPENDED
University of Pennsylvania/Abramson Cancer Center, Philadelphia
RECRUITING
Thomas Jefferson University Hospital, Philadelphia
SUSPENDED
Augusta University Medical Center, Augusta
RECRUITING
Ohio State University Comprehensive Cancer Center, Columbus
ACTIVE_NOT_RECRUITING
Case Western Reserve University, Cleveland
RECRUITING
Cleveland Clinic Foundation, Cleveland
RECRUITING
Wayne State University/Karmanos Cancer Institute, Detroit
RECRUITING
University of Iowa/Holden Comprehensive Cancer Center, Iowa City
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
University of Chicago Comprehensive Cancer Center, Chicago
RECRUITING
University of Oklahoma Health Sciences Center, Oklahoma City
RECRUITING
University of New Mexico Cancer Center, Albuquerque
RECRUITING
Women and Infants Hospital, Providence
Collaborators (1)
NRG Oncology
OTHER
National Cancer Institute (NCI)
NIH